Mergers and Acquisitions
Hepatitis drug maker acquired
Published in Hepatitis Weekly, June 14th, 2004
Through the acquisition, Benitec gains its first in-house advanced therapeutic development program using DNA-directed RNAi (ddRNAi) to target the hepatitis C virus (HCV), the most common blood-borne infection in the U.S.A. Benitec anticipates a ddRNAi- based therapeutic for HCV will enter the clinic in 2005. Under the terms of the agreement, Benitec will issue 7.6m shares to Avocel, representing approximately 9% of the enlarged share capital of Benitec, Ltd.
In...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-06-14)
More Articles from Hepatitis Weekly
- Autoimmune Disease
Diagnoses of zone 3 hepatitis-related autoimmune hepatitis avert cirrhosis - Dialysis
Hemofiltration may trap and destroy hepatitis C virus particles - Drug Detection
Liquid chromatography-tandem mass spectrometry measures PMEA in human sera - Hepatitis C Virus Therapy
Interactions between HCV NS5A protein and 2-tAS counteract interferon - Infectious Disease
Hepatitis E virus causes non-A, non-B, non-C acute hepatitis in Japan - Angiology
Increased vascular HO-1 expression contributes to vasodilation in cirrhotic rats - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
